CST, 72742S, ZBTB46 (F6Z3F) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying ZBTB46. Validated for Western Blotting,Immunoprecipitation,Flow Cytometry (Fixed/Permeabilized). Available in 2 sizes. Highly specific and rigorously validated in-house, ZBTB46 (F6Z3F) Rabbit Monoclonal Antibody (CST #72742) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Flow Cytometry (Fixed/Permeabilized): 1:500 - 1:1500 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation, Flow Cytometry (Fixed/Permeabilized) Specificity / Sensitivity ZBTB46 (F6Z3F) Rabbit Monoclonal Antibody recognizes endogenous levels of total ZBTB46 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ZBTB46 protein. Background Zinc finger and BTB domain-containing protein 46 (ZBTB46) is a member of the broad complex zinc finger protein family, which plays a critical role in transcriptional regulation of immune response, tumor microenvironment, and hematopoietic differentiation (1-3). ZBTB46 is often expressed in dendritic cells (DCs) and their committed progenitors, and is used as a marker to distinguish them from other immune cell types (3,4). ZBTB46 has been shown to act as a transcriptional repressor in these cell types, maintaining a homeostatic steady state; however, it was shown to be non-essential for DC development (3,8). ZBTB46 is also expressed in quiescent endothelial cells and was shown to inhibit cell proliferation (3,4). Recent work has focused on the role of ZBTB46 in tumors. In breast cancer, ZBTB46 was shown to upregulate a long non-coding RNA (lncRNA) that can control breast cancer progression by manipulating tumor immune response (5). A fusion gene consisting of ZBTB46 and WFDC13 is a novel therapeutic target candidate in high-grade serous ovarian carcinoma (6). ZBTB46 is highly expressed and promotes upregulation of inflammation response and neuroendocrine differentiation genes in prostate cancer (7). Alternate Names BTB (POZ) domain containing 4; BTB-ZF protein expressed in effector lymphocytes; BTB/POZ domain-containing protein 4; BTBD4; BZEL; dJ583P15.7; dJ583P15.8; FLJ13502; RINZF; ZBT46; ZBTB46; zinc finger and BTB domain containing 46; Zinc finger and BTB domain-containing protein 46; Zinc finger protein 340; ZNF340 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 80-100 Source/Isotype: Rabbit IgG